Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Equity (2016 - 2025)

Historic Return on Equity for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to 0.64%.

  • ImmunityBio's Return on Equity fell 1800.0% to 0.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.64%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 0.77% for FY2024, which is 3600.0% down from last year.
  • Latest data reveals that ImmunityBio reported Return on Equity of 0.64% as of Q3 2025, which was down 1800.0% from 0.63% recorded in Q2 2025.
  • ImmunityBio's Return on Equity's 5-year high stood at 1.88% during Q3 2021, with a 5-year trough of 0.63% in Q2 2025.
  • Over the past 5 years, ImmunityBio's median Return on Equity value was 0.94% (recorded in 2024), while the average stood at 1.06%.
  • Its Return on Equity has fluctuated over the past 5 years, first plummeted by -804600bps in 2021, then skyrocketed by 2200bps in 2023.
  • Over the past 5 years, ImmunityBio's Return on Equity (Quarter) stood at 1.61% in 2021, then crashed by -41bps to 0.95% in 2022, then rose by 23bps to 1.17% in 2023, then tumbled by -43bps to 0.67% in 2024, then fell by -5bps to 0.64% in 2025.
  • Its last three reported values are 0.64% in Q3 2025, 0.63% for Q2 2025, and 0.76% during Q1 2025.